重症监护及后续医疗的成本与成本效用:一项多中心前瞻性研究
该研究为前瞻性观察性研究,纳入2011年9月至2012年2月芬兰17个ICU收治的成年患者(FINNAKI研究入组者)及同期匹配的住院对照。主要评估3年每质量调整生命年的总医疗成本,并估算预测终生质量调整生命年和资源使用。2869例患者中1839例(64.1%)存活至3年随访;第一年内2212例指数发作存活者中1290例(58.3%)再住院。3年人均累积成本中位数49200美元,ICU成本占3年总成本的21.4%;估计3年每3年质量调整生命年成本为46000美元(95%CI 44700-48500),预测终生每质量调整生命年成本为8460美元(95%CI 8060-8870)。
要点
- 重症监护后3年人均累积成本中位数为49200美元,ICU成本仅占3年总成本的21.4%。
- 第一年内,2212例指数发作存活者中有1290例(58.3%)再住院。
- 与匹配的住院对照相比,重症患者的成本在整个随访期间持续更高。
- 估计3年每3年质量调整生命年成本为46000美元(95%CI 44700-48500),预测终生每质量调整生命年成本为8460美元(95%CI 8060-8870)。
- 院内死亡估计风险超过15%者(基于简化急性生理评分II),3年每3年质量调整生命年成本为61100美元(95%CI 57900-64400)。
适用人群与场景
- 2011年9月至2012年2月入住芬兰17个ICU的成年患者,为FINNAKI研究入组者,以及同期匹配的住院对照。
- 17个ICU提供覆盖芬兰85%成年人口的重症监护。
研究设计与关键结果
- 研究设计为前瞻性观察性研究,纳入2869例患者,其中1839例(64.1%)存活至3年随访。
- 第一年内,2212例指数发作存活者中有1290例(58.3%)再住院。
- 3年人均累积成本中位数为49200美元(四分位距30000-85700美元),ICU成本占3年总成本的21.4%。
- 与匹配的住院对照相比,重症患者的成本在整个随访期间持续更高。
- 估计3年每3年质量调整生命年成本为46000美元(95%CI 44700-48500),预测终生每质量调整生命年成本为8460美元(95%CI 8060-8870)。
- 院内死亡估计风险超过15%者(基于简化急性生理评分II),3年每3年质量调整生命年成本为61100美元(95%CI 57900-64400)。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示重症监护后医疗资源使用显著,且成本持续高于匹配的住院对照,但估计的成本效用价值高;原文未据此给出具体临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The number of critical care survivors is growing, but their long-term outcomes and resource use are poorly characterized. Estimating the cost-utility of critical care is necessary to ensure reasonable use of resources. The objective of this study was to analyze the long-term resource use and costs, and to estimate the cost-utility, of critical care.
DESIGN: Prospective observational study.
SETTING: Seventeen ICUs providing critical care to 85% of the Finnish adult population.
PATIENTS: Adult patients admitted to any of 17 Finnish ICUs from September 2011 to February 2012, enrolled in the Finnish Acute Kidney Injury (FINNAKI) study, and matched hospitalized controls from the same time period.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We primarily assessed total 3-year healthcare costs per quality-adjusted life-years at 3 years. We also estimated predicted life-time quality-adjusted life-years and described resource use and costs. The costing year was 2016. Of 2,869 patients, 1,839 (64.1%) survived the 3-year follow-up period. During the first year, 1,290 of 2,212 (58.3%) index episode survivors were rehospitalized. Median (interquartile range) 3-year cumulative costs per patient were $49,200 ($30,000-$85,700). ICU costs constituted 21.4% of the total costs during the 3-year follow-up. Compared with matched hospital controls, costs of the critically ill remained higher throughout the follow-up. Estimated total mean (95% CI) 3-year costs per 3-year quality-adjusted life-years were $46,000 ($44,700-$48,500) and per predicted life-time quality-adjusted life-years $8,460 ($8,060-8,870). Three-year costs per 3-year quality-adjusted life-years were $61,100 ($57,900-$64,400) for those with an estimated risk of in-hospital death exceeding 15% (based on the Simplified Acute Physiology Score II).
CONCLUSIONS: Healthcare resource use was substantial after critical care and remained higher compared with matched hospital controls. Estimated cost-utility of critical care in Finland was of high value.
参考来源
- Jukarainen S, Mildh H, Pettilä V, et al. Costs and Cost-Utility of Critical Care and Subsequent Health Care: A Multicenter Prospective Study. Crit Care Med. 2020. PMID: 31929342. doi:10.1097/CCM.0000000000004210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。